181 related articles for article (PubMed ID: 35898339)
1. Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA.2 in Shanghai, February-June 2022.
Chen X; Yan X; Sun K; Zheng N; Sun R; Zhou J; Deng X; Zhuang T; Cai J; Zhang J; Ajelli M; Yu H
medRxiv; 2022 Jul; ():. PubMed ID: 35898339
[TBL] [Abstract][Full Text] [Related]
2. Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA.2 in Shanghai, February-June 2022.
Chen X; Yan X; Sun K; Zheng N; Sun R; Zhou J; Deng X; Zhuang T; Cai J; Zhang J; Ajelli M; Yu H
Emerg Microbes Infect; 2022 Dec; 11(1):2800-2807. PubMed ID: 36205530
[TBL] [Abstract][Full Text] [Related]
3. Epidemiological characteristics and transmission dynamics of the outbreak caused by the SARS-CoV-2 Omicron variant in Shanghai, China: a descriptive study.
Chen Z; Deng X; Fang L; Sun K; Wu Y; Che T; Zou J; Cai J; Liu H; Wang Y; Wang T; Tian Y; Zheng N; Yan X; Sun R; Xu X; Zhou X; Ge S; Liang Y; Yi L; Yang J; Zhang J; Ajelli M; Yu H
medRxiv; 2022 Jun; ():. PubMed ID: 35765564
[TBL] [Abstract][Full Text] [Related]
4. Viral kinetics of SARS-CoV-2 following onset of COVID-19 in symptomatic patients infected with the ancestral strain and omicron BA.2 in Hong Kong: a retrospective observational study.
Lin Y; Wu P; Tsang TK; Wong JY; Lau EHY; Yang B; Leung GM; Cowling BJ
Lancet Microbe; 2023 Sep; 4(9):e722-e731. PubMed ID: 37659420
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark.
Hansen CH; Friis NU; Bager P; Stegger M; Fonager J; Fomsgaard A; Gram MA; Christiansen LE; Ethelberg S; Legarth R; Krause TG; Ullum H; Valentiner-Branth P
Lancet Infect Dis; 2023 Feb; 23(2):167-176. PubMed ID: 36270311
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
[TBL] [Abstract][Full Text] [Related]
8. Vaccination effects on post-infection outcomes in the Omicron BA.2 outbreak in Shanghai.
Wu Q; Wang H; Cai J; Ai J; Li Y; Zhang H; Wang S; Sun F; Wu Y; Zhou J; Wang Y; Yu H; Zhang W
Emerg Microbes Infect; 2023 Dec; 12(1):e2169197. PubMed ID: 36644859
[TBL] [Abstract][Full Text] [Related]
9. Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong.
Zhou R; Liu N; Li X; Peng Q; Yiu CK; Huang H; Yang D; Du Z; Kwok HY; Au KK; Cai JP; Fan-Ngai Hung I; Kai-Wang To K; Xu X; Yuen KY; Chen Z
Lancet Reg Health West Pac; 2023 Mar; 32():100660. PubMed ID: 36591327
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.
Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Ackerson BK; Xie F; Takhar H; Ogun OA; Simmons S; Zamparo JM; Valluri SR; Jodar L; McLaughlin JM
Lancet Respir Med; 2023 Dec; 11(12):1089-1100. PubMed ID: 37898148
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: a matched cohort study of adult close contacts.
Zeng T; Lu Y; Zhao Y; Guo Z; Sun S; Teng Z; Tian M; Wang J; Li S; Fan X; Wang W; Cai Y; Liao G; Liang X; He D; Wang K; Zhao S
Respir Res; 2023 Oct; 24(1):246. PubMed ID: 37828565
[TBL] [Abstract][Full Text] [Related]
12. BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study.
Yung CF; Pang D; Kam KQ; Lye DC; Ong B; Chong CY; Tan KB
Lancet Child Adolesc Health; 2023 Jul; 7(7):463-470. PubMed ID: 37201540
[TBL] [Abstract][Full Text] [Related]
13. Epidemiological characteristics and transmission dynamics of the outbreak caused by the SARS-CoV-2 Omicron variant in Shanghai, China: A descriptive study.
Chen Z; Deng X; Fang L; Sun K; Wu Y; Che T; Zou J; Cai J; Liu H; Wang Y; Wang T; Tian Y; Zheng N; Yan X; Sun R; Xu X; Zhou X; Ge S; Liang Y; Yi L; Yang J; Zhang J; Ajelli M; Yu H
Lancet Reg Health West Pac; 2022 Dec; 29():100592. PubMed ID: 36090701
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study.
Antonelli M; Penfold RS; Canas LDS; Sudre C; Rjoob K; Murray B; Molteni E; Kerfoot E; Cheetham N; Pujol JC; Polidori L; May A; Wolf J; Modat M; Spector T; Hammers A; Ourselin S; Steves C
J Infect; 2023 Dec; 87(6):506-515. PubMed ID: 37777159
[TBL] [Abstract][Full Text] [Related]
15. Transmission risks of Omicron BA.5 following inactivated COVID-19 vaccines among children and adolescents in China.
Guo Z; Zeng T; Lu Y; Sun S; Liang X; Ran J; Wu Y; Chong MKC; Wang K; Zhao S
Commun Med (Lond); 2024 May; 4(1):92. PubMed ID: 38762678
[TBL] [Abstract][Full Text] [Related]
16. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods.
Link-Gelles R; Levy ME; Natarajan K; Reese SE; Naleway AL; Grannis SJ; Klein NP; DeSilva MB; Ong TC; Gaglani M; Hartmann E; Dickerson M; Stenehjem E; Kharbanda AB; Han J; Spark TL; Irving SA; Dixon BE; Zerbo O; McEvoy CE; Rao S; Raiyani C; Sloan-Aagard C; Patel P; Dascomb K; Uhlemann AC; Dunne MM; Fadel WF; Lewis N; Barron MA; Murthy K; Nanez J; Griggs EP; Grisel N; Annavajhala MK; Akinseye A; Valvi NR; Goddard K; Mamawala M; Arndorfer J; Yang DH; Embí PJ; Fireman B; Ball SW; Tenforde MW
JAMA Netw Open; 2023 Mar; 6(3):e232598. PubMed ID: 36920396
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of BNT162b2 and Sinovac vaccines against the transmission of SARS-CoV-2 during Omicron-predominance in Hong Kong: A retrospective cohort study of COVID-19 cases.
Zhao S; Guo Z; Sun S; Hung CT; Leung EYM; Wei Y; Wang H; Li K; Yam CHK; Chow TY; Gao J; Jia KM; Chong KC; Yeoh EK
J Clin Virol; 2023 Sep; 166():105547. PubMed ID: 37453162
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 incidence, transmission and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-2021.
Cohen C; Kleynhans J; von Gottberg A; McMorrow ML; Wolter N; Bhiman JN; Moyes J; du Plessis M; Carrim M; Buys A; Martinson NA; Kahn K; Tollman S; Lebina L; Wafawanaka F; du Toit J; Xavier Gómez-Olivé F; Dawood FS; Mkhencele T; Sun K; Viboud C; ; Tempia S
medRxiv; 2021 Dec; ():. PubMed ID: 34909794
[TBL] [Abstract][Full Text] [Related]
19. Real-world effectiveness of the heterologous SOBERANA-02 and SOBERANA-Plus vaccine scheme in 2-11 years-old children during the SARS-CoV-2 Omicron wave in Cuba: a longitudinal case-population study.
Toledo-Romaní ME; Valenzuela-Silva C; Montero-Díaz M; Iñiguez-Rojas L; Rodríguez-González M; Martínez-Cabrera M; Puga-Gómez R; German-Almeida A; Fernández-Castillo S; Climent-Ruiz Y; Santana-Mederos D; López-González L; Morales-Suárez I; Doroud D; Valdés-Balbín Y; García-Rivera D; Van der Stuyft P; Vérez-Bencomo V
Lancet Reg Health Am; 2024 Jun; 34():100750. PubMed ID: 38699214
[TBL] [Abstract][Full Text] [Related]
20. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.
Tan CY; Chiew CJ; Pang D; Lee VJ; Ong B; Lye DC; Tan KB
Lancet Infect Dis; 2023 Jul; 23(7):799-805. PubMed ID: 36924786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
